{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["487(1)"],"submitter":["Hommerding O"],"funding":["Universitätsklinikum Bonn"],"pubmed_abstract":["The prognostication of individual disease trajectory and selection of optimal therapy in patients with localized, low-grade prostate cancer often presents significant difficulty. The phosphatase and tensin homolog on chromosome 10 (PTEN) has emerged as a potential novel biomarker in this clinical context, based on its demonstrated prognostic significance in multiple retrospective studies. Incorporation into standard clinical practice necessitates exceptional diagnostic accuracy, and PTEN's binary readout-retention or loss-suggests its suitability as a biomarker. This multi-institutional ring trial aimed to validate the diagnostic precision of PTEN immunohistochemistry in localized, low- to intermediate-risk prostate cancer, across ten university pathology institutes in Germany. The trial i"],"journal":["Virchows Archiv : an international journal of pathology"],"pagination":["87-96"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12289804"],"repository":["biostudies-literature"],"pubmed_title":["High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial."],"pmcid":["PMC12289804"],"pubmed_authors":["Semjonow A","Reis H","Kristiansen G","Schmid M","Linxweiler J","Schildhaus HU","Brasen JH","Darr C","Wulf AL","Baretton G","Seidl M","Esposito I","Stahl PR","Kreipe H","Schlack K","Hartmann W","Abbas M","Hommerding O","Lopez-Cotarelo C","Scherping A","Dressler FF","Hartmann A","Saar M","Weber F","Ellinger J","Lafos M","Sailer V","Tischler V","Bernhardt M","Kreft T","Sommer U","Breyer J","Heitplatz B","Erber R","Wullich B"],"additional_accession":[]},"is_claimable":false,"name":"High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.","description":"The prognostication of individual disease trajectory and selection of optimal therapy in patients with localized, low-grade prostate cancer often presents significant difficulty. The phosphatase and tensin homolog on chromosome 10 (PTEN) has emerged as a potential novel biomarker in this clinical context, based on its demonstrated prognostic significance in multiple retrospective studies. Incorporation into standard clinical practice necessitates exceptional diagnostic accuracy, and PTEN's binary readout-retention or loss-suggests its suitability as a biomarker. This multi-institutional ring trial aimed to validate the diagnostic precision of PTEN immunohistochemistry in localized, low- to intermediate-risk prostate cancer, across ten university pathology institutes in Germany. The trial i","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-17T13:41:58.906Z","creation":"2025-08-28T03:04:47.073Z"},"accession":"S-EPMC12289804","cross_references":{"pubmed":["39653828"],"doi":["10.1007/s00428-024-03999-y"]}}